# Phase Ib Study of FURMONERTINIB in Patients with NSCLC Having Exon 20 Insertion Mutation

> **NCT04958967** · PHASE1 · WITHDRAWN · sponsor: **Allist Pharmaceuticals, Inc.**

## Conditions studied

- NSCLC

## Interventions

- **DRUG:** Furmonertinib 240mg
- **DRUG:** Furmonertinib 160mg

## Key facts

- **NCT ID:** NCT04958967
- **Lead sponsor:** Allist Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-10-01
- **Primary completion:** 2022-05-01
- **Final completion:** 2022-08-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The protocol need to review
- **Last updated:** 2025-03-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04958967

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04958967, "Phase Ib Study of FURMONERTINIB in Patients with NSCLC Having Exon 20 Insertion Mutation". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT04958967. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*